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Abstract
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic 
cells. In these cells, it down-regulates activated tyrosine kinases at the cell surface resulting in an 
antiproliferative effect. To date, no studies have examined activities of LNK in solid tumors. In 
this study, we found by in silico analysis and staining tissue arrays that the levels of LNK 
expression were elevated in high grade ovarian cancer. To test the functional importance of this 
observation, LNK was either overexpressed or silenced in several ovarian cancer cell lines. 
Remarkably, overexpression of LNK rendered the cells resistant to death induced by either serum 
starvation or nutrient deprivation, and generated larger tumors using a murine xenograft model. In 
contrast, silencing of LNK decreased ovarian cancer cell growth in vitro and in vivo. Western blot 
studies indicated that overexpression of LNK upregulated and extended the transduction of the 
mitogenic signal, whereas silencing of the LNK produced the opposite effects. Furthermore, 
forced expression of LNK reduced cell size, inhibited cell migration and markedly enhanced cell 
adhesion. LC-MS identified 14-3-3 as one of the LNK binding partners. Our results suggest that in 
contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive 
signal transduction modulator in ovarian cancers.
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Introduction
The adaptor protein LNK (SH2B3) is a key negative regulator of the signaling pathway of 
hematopoietic receptors activated by growth factors 1, 2, thus playing a critical role in 
hematopoiesis 3. The protein contains a N-terminal proline-rich region which mediates 
dimerization, a pleckstrin homology (PH) domain and a Src homology 2 (SH2) domain 
which specifically binds to phosphorylated tyrosines and mediates signal transduction 1. 
Previous studies showed that LNK knockout mice had splenomegaly and abnormal 
lymphoid and myeloid homeostasis 4, 5. Subsequent studies revealed that LNK inhibited the 
activating signals mediated by thrombopoietin (TPO) 6–8 and erythropoietin (EPO) 9. On the 
other hand, overexpression of LNK inhibited proliferation of hematopoietic transformed 
cells through the suppression of the kinase activity of oncogenic JAK2 V617F 10, 11, MPL 
W515L 12, c-KIT 13, 14, c-FMS 15 , PDGFR/FIP1L1-PDGFRα and TEL-PDGFRβ 16, as 
well as FLT3-ITD 17. Recently, LNK mutations have also been found in patients with 
myeloproliferative neoplasms (MPN) 18–21, early T cell acute lymphoblastic leukemia 
(ALL) 22 , Ph-like ALL 23 , B-precursor ALL 24 and Down syndrome-related myeloid 
disorders 25. The mutational loss of function of LNK in hematopoietic cells releases its 
inhibitory activity against the activated tyrosine kinase receptors and its downstream JAK-
STAT pathway, resulting in enhanced hematologic cell proliferation, thus fostering the 
development and progression of these hematopoietic neoplasms 10. The resultant phenotype 
is reminiscent of the MPN-like features of LNK−/− mice 26.
Most of the studies that have explored the function of LNK focused on either normal or 
transformed hematologic cells; recently, several studies have explored the effects of LNK on 
the function of normal endothelium cell 27–29. To our knowledge, the role of LNK in solid 
tumors has not been addressed. Previously, while studying hematopoiesis, control 
experiments noted that forced overexpression of LNK did not inhibit the growth of several 
nonhematopoietic cell lines (NIH3T3 and 293T) 6. In an overview survey, we found that 
selected solid cancers expressed LNK, and forced overexpression of LNK in several solid 
cancer cell lines did not have a significant effect on their proliferation, suggesting LNK may 
have a different role in solid tumor cells compared to hematologic dyscrasias 30. This 
observation prompted us to do an in depth study of the effect of LNK in ovarian cancer 
cells. We chose this cancer because we previously noted that some ovarian cancer cell lines 
had detectable levels of LNK mRNA 30.
Materials and methods
Antibodies and reagents
The following antibodies were used in this study: anti-human LNK antibody [AF5888, R&D 
system Inc, a sheep IgG against E.coli derived recombinant human LNK protein (amino 
acids 427–575)]; murine anti-β-actin monoclonal antibody (Sigma); V5 and pan 14-3-3 
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antibody (Abcam); antibodies against p-JAK2 (Tyr1007/1008), JAK2, p-p38 (Thr180/
Tyr182), p-ERK1/2 (Thr202/Tyr204), p-JNK1/2 (Tyr183), p-PDK1 (Ser243), p-P70S6 
(Thr421/Ser424), p-GSK3beta (Ser9), p-AKT (Ser473) and AKT, p-PI3K p110δ (Tyr485) 
(from either Cell Signaling Technology or Santa Cruz) and p-FAK Tyr861 (Epitomics).
Cell lines and cell culture
Ovarian cancer cell lines OVCA433, C13, A2008, CAOV-2 (provided by Ruby Huang, 
NUS) and melanoma cell lines M285, M368 (kindly provide by Antoni Ribas, UCLA) were 
maintained in RPMI 1640 containing 10% fetal bovine serum (FBS) with penicillin and 
streptomycin. The ovarian cancer cell line OVCAR5 was maintained in the same medium 
with 10 μg/ml insulin; OV7 and OV56 were maintained in DMEM Hi-Glucose/Ham’s F-12 
[1:1] plus 10% FBS, 0.5 μg/mL hydrocortisone and 10 μg/mL insulin. HEK293T cells were 
cultured in DMEM medium with 10% FBS. Cells were grown at 37°C with 5% CO2 in 
humidified air.
Lentivirus and stable cell line generation
The pLKO.1-puro-CMV-TurboGFP lentivirus plasmid (SHC003) was obtained from Sigma. 
The entire coding region of huLNK, including the HIS tag and V5 tag, was amplified from 
pcDNA3 LNK using primers TGAGCTAGCATGAACGGGCCTGCCCTGCAGCC (Nhe I) 
and AAACACGTGCTCGAGCGGCCGCCACTGT (Pml I). The PCR product was ligated 
to pGEM-T vector and validated by Sanger sequencing. This construct was digested with 
Nhe I and Pml I, the LNK containing fragment was gel purified, and the GFP coding 
fragment of pLKO-CMV-GFP vector (SHC003) was replaced with the LNK open reading 
frame (pLKO-CMV-LNK). For gene silencing, shRNA plasmids targeted to LNK 
[TRCN0000265715 (shRNA15), TRCN0000265716 (shRNA16), TRCN0000256095 
(shRNA95) and Scramble shRNA SHC002 were purchased from Sigma. shRNA plasmids 
targeted to AKT1 (TRCN0000010174), 14-3-3 Q (YWHAQ TRCN0000078169), 14-3-3 Z 
(YWHAZ TRCN0000029404) and 14-3-3 G (YWHAG TRCN0000078158) were generated 
according to the protocol described by Addgene (http://www.addgene.org/tools/protocols/
plko/). The sequences of all the shRNA constructs were confirmed by Sanger sequencing 
using the U6 primer.
Ovarian cancer tissue array analysis
Human ovarian cancer tissue array (OVC1021) was purchased from Biomax US. Specifity 
of LNK antibody was validated by Immunohistochemical staining (IHC) of formalin fixed 
and paraffin embedded blocks either of silenced or overexpressed LNK OVCA433 cell. 
Detail process of IHC is described in the Supplemental Material.
Murine xenograft model
In vivo cell proliferative effects after either gain or lost of LNK was studied in a murine 
xenograft model. 5–6 weeks old Nod-SCID mice were used for the study. 2 million 
(CAOV2 and A2008) or 6 million (OVCAR5) cells were resuspened in 100 μl FBS and 100 
μl Matrix gel (BD Biosciences), and subcutaneously injected into both flanks of immune 
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deficient Nod-SCID mice. The mice were sacrificed, and the tumors were excised and 
weighted at the end of the experiments (days 18–28).
Microarray analysis
Microarray analyses were performed in triplicate using OVCA433 cells overexpressing 
LNK, compared to control cells containing GFP. The array hybridization was performed 
with Illumina Human HT-12 v4 Expression BeadChip, the pathway analysis was 
accomplished with KEGG and Biocarta database. Real time RT-PCR was performed to 
validate the significantly changed genes.
Co-Immunoprecipitation and LC-MS analysis
LNK overexpressing cell lines were place into the protein lysis buffer (0.5% Nonidet P40, 
50 mM Tris/HCl pH 8.0, 150 mM NaCl with protease inhibitor cocktail and phosphatase 
inhibitors NaF and Na3VO4) at 4°C for 15 min, and centrifuged at 12000 rpm (15 min, 4°C) 
to remove cell debris. Protein lysates were shaken overnight with V5 antibody at 4°C and 
collected by precipitation with protein A/G beads. After washing with protein lysis buffer 3 
times, the protein binding to the protein A/G beads were eluted with 5 x SDS loading dye; 
the eluted samples were subsequently used for LC-MS analysis.
Method in Supplemental Material
Detailed methods for Lentivirus packaging, western blot, immunofluorescence microscopy 
and the assays for cell proliferation, cell adhesion and detachment, cell motility and 
invasion, are provided in the Supplemental Material.
Result
Elevated expression of LNK in ovarian cancers
Previously, others 6 and our group 30 showed that overexpression of LNK inhibited cell 
growth and caused cell death in many leukemia cell lines, but similar experiments 
performed in several solid tumor cell lines had little effect on their proliferation 30, 
suggesting LNK might have a different role in solid tumor cells compared to those of the 
hematopoietic system. In silico analyses shown that rather than being down-regulated as 
anticipated for a tumor suppressor, LNK is upregulated in several types of tumors including 
skin (melanoma), kidney and ovarian cancers (Fig. 1A). Meanwhile, cancer copy number 
data from TCGA suggests the LNK locus is amplified in several solid tumors including 
sarcoma (5.8%, 3/52 cases in TCGA dataset or 2.4% 5/207 cases in MSKCC/Broad dataset), 
bladder cancer (3.8%, 1/26 cases) and ovarian cancer (2.3%, 7/311 cases) (Supplemental 
Fig. 1). Here, we focused on ovarian cancer. LNK expression was examined in the 
microarray data of 1,538 ovarian cancer patient samples and 142 ovarian cancer cell lines 
(molecular ovarian cancer subtypes were classified as described in 31). Among the five 
different ovarian subtypes (Epi-A, Epi-B, Mes, Stem-A and Stem-B), LNK mRNA 
expression is significantly elevated in the mesenchymal subtype in both patient samples and 
cell lines (Fig. 1B). Mesenchymal subtype includes more advanced staged including 
metastatic tumours; this subtype is associated with poorer outcomes 31. This was further 
analyzsed using cBio cancer genomics portal (http://www.cbioportal.org/public-portal/
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index.do) of the TCGA dataset. A total of 316 serous ovarian cancer sample were separated 
into LNK high and low expression groups, Patients with a higher LNK expression showed a 
worse outcome compared to those with a lower LNK expression (Fig.1C, left). In contrast, 
those patients having relative low LNK expression had a better survival (Fig.1C, right).
In addition, moderate LNK immunohistochemical staining was observed in many serous 
cystadenocarcinoma and endometrioid carcinoma samples, expecially in high grade disease 
(Figs. 1D, E and Supplemental Figs. 3–5); only weak staining was observed in the benign 
serous cystadenoma and negative staining occurred in the normal ovary tissue.
Overexpression of LNK renders the cells resistant to cell death
Subsequently, we examined LNK protein expression in several ovarian cancer and 
melanoma cell lines by western blot. Unexpectedly, we found the LNK protein levels were 
significantly upregulated during serum-starvation which returned to baseline levels when the 
cells were restored to complete medium containing 10% FBS. This was noted in the ovarian 
cancer cell lines A2008 and C13, as well as the melanoma cell lines M285 and M368 (Fig. 
1F). We also observed this phenomenon in cells which stably contained a LNK expression 
vector whose level of LNK transcription was constantly driven by the CMV promoter (Fig. 
1G). Thus, accumulation of LNK protein with serum starvation is probably a post-
translational event.
To test the functional importance of this finding, we studied both forced-expression and 
silencing of LNK in several ovarian cancer cell lines. Overexpression of LNK in the ovarian 
cancer cells OVCA433 significantly enhanced their cell survival during prolonged serum 
starvation. After 9 days culture in serum-free RPMI medium, over 60% of the control GFP 
cells were dead. In contrast, almost all the LNK overexpressing cells survived, suggesting 
that LNK promoted cell survival in serum-free adverse conditions [Fig. 2A (left), Fig. 2B]. 
In another set of complementary experiments, LNK protected ovarian cancer cells in even 
more adverse growth condition. LNK overexpressing cells displayed significantly higher 
survival rates than the GFP control cells after eliminating serum and growing in either 50% 
or 10% RPMI culture medium (replacing RPMI with PBS) (Fig. 2A, upper panel). Also, 
overexpression of LNK rendered the ovarian cancer cells resistant to death during exposure 
to either PI3 kinase inhibitor (LYS294002), multi-targeted receptor tyrosine kinase inhibitor 
(Sunitinib), inhibitor of transcription (Actinomycin-D), chemotherapy drug (Pacitaxel) or 
HSP90 inhibitor (17-DMAG), further confirming the pro-survival effect produced by the 
gain of LNK expression (Fig. 2A). This phenomenon was also observed to various degrees 
in three other ovarian cancer cell lines: CAOV2, OVCAR5 and C13 cultured in the absence 
of serum with the addition of only 10% RPMI and 90% PBS (Fig. 2C). Western blot 
revealed that the p-AKT pro-survival signal pathway in the LNK expressing cells was 
strongly activated during starvation (Fig. 2D). Phosphorylated P70S6 and JNK1/2 were also 
increased (Fig. 2D). When both cell lines (GFP or LNK) were infected with lentivirus 
containing shRNA targeted to AKT1, the pro-survival effect of LNK was diminished in the 
presence of serum starvation, suggesting that LNK activates the p-AKT pathway and 
protects the cells from cell death (Fig 2E).
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LNK promotes tumor growth in an in vivo murine xenograft model
Under optimal growth conditions, forced expression of LNK in five out of 7 ovarian cancer 
cell lines had little effect on cell proliferation (Fig. 3A), while OV56 and OVCA433 had a 
slight inhibition of their cell growth. On the other hand, stable silencing of LNK using three 
different shRNAs slowed the proliferation of six of 8 ovarian cancer cell lines (Fig. 3B), 
including A2008, CAOV2, C13, OVCA433, OVCAR5 and OV56 (Fig. 3B).
To observe the in vivo effect of LNK on cell growth, murine xenograft models were 
established by subcutaneous injection of either CAOV2, OVCAR5 or A2008 cells having 
either forced expression or silencing of LNK. Tumor sizes and weights were increased in all 
the cell lines with forced expression of LNK, expecially the OVCAR5 tumors (Fig. 3C, p 
value 0.03). In contrast, silencing of LNK in these cell lines reduced their tumor sizes and 
weights. Taken together, LNK promotes tumor growth in three murine xenograft models. 
Western blot and IHC staining confirmed the LNK overexpression in these tumors (Figs. 
3D, E).
LNK regulates mitogenic signalling
To investigate potential mechanisms by which LNK regulates cellular proliferation, major 
mitogenic signaling pathways were examined upon either gain or loss of LNK expression. In 
agreement with our notion that LNK might be a positive regulator in these cell lines, LNK 
expression enhanced several signaling pathways which are critical for cell proliferation and 
survival in two ovarian cancer cell lines, OVCA433 and OVCAR5 (Fig. 4A). Forced 
expression of LNK increased phosphorylation of AKT and JNK1/2 in both cell lines, as well 
as increasing phosphorylation levels of PDK1 and p70S6 in OVCA433, and phosphorylation 
level of p38 in OVCAR5. Of interest, similar to hematopoietic cells, LNK attenuated the 
modest basal levels of p-JAK2 in OVCA433 (Fig. 4A). In contrast, stably silenced LNK 
using two shRNA in three ovarian cancer cell lines (A2008, CAOV2 and OVCAR5) 
resulted in down-regulation of expression of p-PDK1, p-AKT, p-GSK3β and MAPK kinase 
(p-p38 and p-JNK1/2) (Fig. 4B). In further experiments, we examined in detail the 
alterations of mitogenic signaling upon serum stimulation in several ovarian cancer cell lines 
having either forced expression or silencing of LNK (Figs. 4C, D, E, F, G). These cells were 
serum-starved (SS) overnight followed by serum stimulation for different durations (20 to 
120 mins). The serum stimulated LNK overexpressing cells showed higher levels of p-AKT, 
p-P70S6, p-ERK1/2 compared to similarly treated control cells, especially the OVCA433 
and A2008 cells (Fig. 4C), while silencing of LNK generally generated the opposite effect 
(Figs. 4E, F, G, right panels).
In agreement with our observations, a significant correlation can be noted between the 
endogenous levels of LNK and the activation status of MAPK pathway in the TCGA 316 
ovarian cancer samples [Reverse Phase Protein Array (RPPA)]. Ovarian cancer samples 
with high expression of LNK displayed high levels of p-AKT, p-mTOR, p-MAP2K1 and p-
MAPK (p-ERK1/2, p-JNK1/2 and p-p38), whereas samples with lower LNK mRNA 
expression had lower phosphorylation levels of the above proteins (except p-AKT) (Figs. 
4H, I and J).
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LNK enhances cell attachment and inhibits cell migration
During cell passage, we noted that stable LNK overexpressing OVCA433 cells displayed a 
strong attachment to the tissue culture plate, requiring either a longer duration or higher 
concentration of trypsin to release them from the plates compared to control cells. In 
contrast, stable knockdown of LNK in these cell lines slightly reduced the length of 
exposure to trypsin in order to release them from the plates (data not shown). We, therefore, 
considered that LNK enhanced cell adhesion. To explore this hypothesis, OVCA433 cells 
were allowed to adhere to culture dishes in six well plates until they reached confluence. 
Plates were washed with PBS (not containing calcium) and cultured in different percentages 
of PBS (95–100%) and RPMI (5–0%) for 3 hours. This lead to disruption of calcium-
dependent cell contact junction/adhesion and slowly release the cells. As anticipated, 
compared to GFP control cells, those with forced expression of LNK protein significantly 
retained their cell attachment to the plates as the culture media were replaced with 
increasing amounts of calcium-free PBS (Fig. 5A). In the presence of 99% PBS for 3 hours, 
a total of 69% of the LNK expressing cell were still attached to the plates, compared to 18% 
of control cells.
Cell migration was measured using the wound healing assay (Fig. 5B). At 16 hours after the 
wound scratch, LNK overexpressing OVCA433 cells maintained a nearly intact gap. In 
contrast, the GFP-control cells nearly closed the healing gap, indicating that LNK indeed 
plays a role in regulation of cell migration. In addition, transwell experiments found that 
LNK overexpressing ovarian cancer cells migrated significantly less than the GFP control 
cells (Fig. 5C).
LNK regulates cells size
Consistent with the notion that LNK may play a role in the cytoskeleton organization and 
regulate cellular shape, overexpression of LNK reduced the cell diameter of five of 6 
ovarian cancer cell lines (Fig. 5D). In contrast, silencing of LNK generated the opposite 
effect (Fig. 5E). The cell diameter increased to various extents in the six ovarian cancer lines 
having one of three shRNA targeted to different regions of LNK. This was most prominent 
in A2008, C13, OVCA433 and SKOV3 ovarian cancer cell lines (Fig. 5E).
Pathway analysis of microarray data
RNA microarray analysis was performed to examine the gene expression changes after 
forced expression of LNK in OVCA433. Compared to vector control cells, the experimental 
cells had a prominent upregulation/alteration of genes related to extracellular matrix (ECM) 
receptor interaction (p-value 7.91 E−4), cell adhesion/attachment (p-value 1.46 E−4), and 
molecules associated with cell-cell tight junctions (Fig. 6A). A heat map displays genes with 
altered expression related to cell adhesion, p53 signaling and the JAK-STAT pathway (Fig. 
6B).
Quantitative real time RT-PCR was performed to confirm some of the interesting genes. 
Several members of the cadherin family (CDH1, 3, 5, 10) (contributes to cell attachment) 
and members of the claudin family (CLDN3, 6, 7, 23) (critical for the cell-cell tight junction 
formation) were indeed upregulated in the LNK overexpressing cells (Fig. 6C, top panel). 
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Additional genes related to cell adhesion and cell-cell connection including AMOT, 
CGNL1, CGN, Laminin (LAMA3) and integrin (ITGA4) were also upregulated in the LNK 
overexpressing cells, as confirmed by real time PCR (Fig. 6C, upper panel). In contrast, two 
matrix metallopeptidases associated with extracelluar matrix degradation and enhanced cell 
migration (MMP9 and MMP7) were downregulated in the LNK overexpressing cells (Fig. 
6C, upper panel). Interestingly, several cyclins (CCNB1, CCND2 and CCNG2), as well as 
BCL2L1 (a potent inhibitor of cell death) were upregulated in cells with overexpression of 
LNK, which is consistent with their resistance to cell death. In addition, two phosphatases 
(DUSP5 and DUSP6) were down-regulated in the LNK overexpressing cells (Fig. 6C, lower 
panel), which may contribute to the elevated MAPK signaling in the LNK overexpressing 
cells.
Liquid chromatography–mass spectroscopy (LC-MS)
To investigate further the potential mechanism by which LNK regulates signal transduction, 
LC-MS was performed to identify possible LNK binding proteins. LNK and the binding 
proteins were initially co-immunoprecipitated with V5 antibody from OVCA433 cells stably 
expressing V5 tagged LNK; the immunoprecipitated protein complex was extensively 
washed and analyzed by LC-MS. Proteins also present in the control (OVCA433 cells stably 
expressing GFP immunoprecipitated with either V5 antibody or normal IgG) were removed 
from the results, and the candidate binding partners are summarized (Fig 7A). The protein 
14-3-3, recently identified as a LNK binding partner in hematologic cells 32, appears at the 
top of the list (Fig. 7A). This binding was further confirmed by immunoprecipitation and 
western blot (Fig. 7B), suggesting that LNK also bound to this scaffold protein in ovarian 
cancer cells. Interestingly, several binding candidates (MLL3, ATRX, NCOR2, and 
NCOR7) are nuclear protein having important role in regulation of histone methylation, 
chromatin remodeling and control of transcription. Their presence on the list raises the 
possibility that LNK may also be active in the nucleus. SH2B1β, another member of the 
same family as LNK, shuttles between the plasma membrane, cytosol and nucleus; and its 
nuclear-cytosol cycling is critical to promote NGF-mediated preneuronal cell 
differentiation 33. Our protein fractionation and western blot experiments showed a small 
amount of LNK was indeed present in the nuclear protein fraction (Figs. 7C); the role of the 
nuclear LNK requires further study.
Three phosphorylation modification of LNK were identified by mass spectroscopy (Fig 7D): 
S-103, S-150 and S-330, and the phosphorylation modification was further confirmed by 
antibodies specifically targeting total phosphorylated S/T (Fig. 7B). Among these sites, 
Serine-150 is the human LNK homolog of murine LNK S-129 (Fig.7E), which after 
phosphorylation allows LNK to bind avidly to 14-3-3 32. Phosphorylation (S-150) of human 
LNK is also predicted to mediate binding of the 14-3-3 (http://scansite.mit.edu/). This is 
consistent with our immunoprecipitation studies showing that 14-3-3 is bound to LNK (Figs. 
7A, B). Also, both sites (S-150 and S-330), and their surrounding amino acids are highly 
conserved across many species (Fig.7E), suggesting their biological importance. Our MS 
results covered the peptide fragments containing Y44, Y203, Y273, Y401, Y555 and Y572 
of LNK, and no phosphorylation of tyrosine residues in these fragments was detected.
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We further investigate the binding effect of the 14-3-3 to the LNK protein. OVCAR5 cells 
with forced expression of LNK was further infected with lentivirus containing either non-
target shRNA or shRNA mixture targeted to three 14-3-3 members: tau, zeta and gamma. 
Reduction of the cell diameter (Fig 7F) and generating slightly larger tumors (Fig 7G) was 
observed in these cells, compared to tumors with forced expression of LNK alone (Fig 7G). 
Taken together, these result suggested release or loss of the 14-3-3 binding will further 
enhanced the effect of LNK. 14-3-3 may suppress the activity of LNK by modulating the 
amount of “freely available” LNK to participate in regulation of the signaling pathway. Base 
on these observation, an working model of LNK in ovarian cancer is proposed 
(Supplemental Fig 9).
Discussion
LNK is a well-studied tumor suppressor gene in hematopoiesis 6, 34, 35. It is mutated in 
hematopoietic malignancies including 3~5% of MPN samples, 10% of MPN evolved to 
acute myeloid leukemia, and 5% of early T cell leukemia (reviewed in 34). These mutations 
appear to be a loss of function, i.e. dampening an activated tyrosine kinase. Paradoxically, 
we show that LNK can exert tumor survival properties in ovarian cancer cells and promote 
tumor growth in in vivo models. Growth-factor/cytokine signaling often governs the uptake 
of nutrients, which in turn determines concentrations of intracellular metabolites. Nutrient 
depletion, as well as other stresses may trigger altered cellular pathway leading either cell 
survival or apoptosis 36. The AKT and MAPK pathways are among the major downstream 
signals activated by growth factors, which are often deregulated in cancer. Increased 
expression of LNK in ovarian cancer cells up-regulated and prolonged the activation of 
AKT and MAPK and rendered the cells resistant to death induced by either serum/nutrient 
starvation or drug treatments. In contrast, silencing of LNK in these cells decreased 
activated AKT and MAPK signaling and slowed their cell proliferation. A similar 
observation has been reported recently, showing that LNK protected normal endothelium 
cells from death and rendered them resistant to apoptosis induced by tumor necrosis factor 
(TNF) and actinomycin-D 29, suggesting this pro-survival effect of LNK is not only limited 
to ovarian cancer cells. Our RNA array analysis suggested that metabolic pathways are 
enhanced in cells overexpressing LNK. We speculate that LNK enhancement of signal 
transduction pathways (e.g. AKT and MAPK pathways), allows for sufficient nutrient 
uptake, even when cells are exposed to low nutrient/stress conditions, which in turn enables 
the cells to maintain their metabolic needs.
The mammalian Target of Rapamycin (mTOR) plays a central role in regulating cell growth 
(cell mass) and cell proliferation (cell numbers) in response to environmental cues such as 
nutrient availability and different types of stress 37. LNK overexpression in ovarian cancer 
cells enhanced their proliferation and reduced their cell size, while silencing of LNK had the 
opposite affects. The phosphorylation levels of AKT ( upstream of mTOR) and p70S6 
(downstream of mTOR) were both increased upon LNK overexpression, suggesting that the 
mTOR pathway is up-regulated by LNK in ovarian cancer cells.
The in vivo xenograft experiments showed that LNK can promote cell growth and generate 
bigger tumor. Why does LNK appear to function differently in leukemia cells verses ovarian 
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cancer/normal endothelial cells? LNK does not have enzymatic activity; its function is 
totally dependent on its binding partners. LNK may behave similar to a “buffer molecule” 
modulating direction, amplitude and duration of signal transduction of the binding partner. 
Notably, the other two members [SH2B1 and APS (SH2B2)] of this family of proteins, 
share similar sequence homologies 38–40, and their stimulatory and inhibitory roles also 
appear to be cell-type and pathway dependent. Many hematopoietic malignancies including 
MPN, act as classical “activated kinase diseases” driven by a mutant activated receptor 
tyrosine kinase (e.g., FLT3-ITD, mutant c-KIT) or the downstream kinase e.g. JAK2 to 
propel proliferation and survival. Typically, these activated mutant tyrosine kinases 
phosphorylate LNK at a tyrosine residue which becomes the scaffold for other SH2 domain 
containing proteins to attenuate the activated tyrosine kinase. This represents a feedback 
mechanism. In contrast, most of the ovarian cancers contain mutations associated with 
alterations of pathway signaling by RB, PI3K/RAS, Notch, BRCA1/2 and the FOXM1 
transcription factor 41. Thus, we hypothesize that these ovarian cancer cells do not depend 
on either mutant, activated JAK2 and/or mutant, activated type III receptor tyrosine kinase 
pathways. Instead, oncogenic drivers of ovarian cancer cells are downstream of these 
receptor tyrosine kinases. Thus, LNK may not have a significant inhibitory effect on 
transformed epithelial cells. Meanwhile, a recent study in drosophila revealed that LNK 
regulates and enhances the insulin signaling by binding to the insulin receptor 42, 43. Female 
flies who are homozygously mutant for LNK have much smaller ovaries containing few 
oocytes and are sterile due to an arrest in oogenesis 42. These studies suggest that LNK is 
required for normal ovarian development in the Drosophila.
Our studies show that LNK affects cell adhesion, ECM interaction and possibly the integrin 
pathway of ovarian cancer cells. We observed that overexpression of LNK inhibited cell 
migration. Concordantly, bone marrow mast cell (BMMC) from LNK −/− mice were reported 
to display increased migration to a cytokine compare to the wild type mast cells 13. The 
authors attributed the phenotype of these BMMC to upregulation of the RAC1, p-JNK1/2 
and p-P38 pathway in the LNK−/− mice cells 13. However, in ovarian cancer cells, our data 
suggest that the activated p-JNK1/2 and p-P38 pathway is associated with LNK expression 
and decreased migration. Consistent with our results, a recent study suggested that 
overexpression of LNK inhibits cell migration of normal endothelial cells; and the authors 
reached the conclusion that this phenomenon is associated with enhanced turnover of focal 
adhesion complexes and activation of the integrin pathway 27. Additionally, SH2B1 recently 
was also found to play a role in the regulation of focal adhesion complexes 44. Of particular 
interest, our microarray analysis showed that a number of genes related to cell adhesion and 
ECM interaction (e.g., E-cadherin and the cell-cell tight junction claudin family members), 
are up-regulated in ovarian cancer cells that have high expression of LNK. At the same time, 
our mass spectroscopy results suggest that LNK might bind to the small G protein RAB21, 
which is critical for integrin internalization, trafficking and redistribution 45. Together, our 
data suggest that LNK may enhance cell attachment and attenuate cell migration by multiple 
mechanisms.
Besides participating in cell adhesion and ECM-interaction, pathway analysis suggested a 
possible role of LNK in the JAK2-STAT signaling pathways; this is consistent with the 
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function of LNK in hematopoietic cells. Interestingly, pathway analysis also suggests that 
LNK participates in the amino acid metabolism pathway (Fig. 6A). In line with this 
observation, a prior study indicated that LNK was dysregulated when cells were placed in a 
cysteine-free environment 46.
Our mass spectroscopy results suggest that some nuclear proteins interact with LNK, which 
prompted us to examine the subcellular localization of LNK. Our protein fractionation 
studies found a small amount of LNK localized in the nucleus, implying that LNK may have 
some biological function in the nucleus. Of note, the well known binding partner of LNK, 
JAK2, enters the nucleus and regulates transcription by phosphorylating the core histone 
H3 47. Although we did not identify JAK2 binding to LNK by our mass spectroscopy, this is 
worthy of further exploration. Also of interest, several proteins related to the endocytic 
pathway (CLINT1, RAB21 and LYST) appear to bind to LNK as detected by mass 
spectroscopy. Generally in hematopoietic cells upon ligand stimulation, their receptor 
tyrosine kinases enter the endocytosis pathway and in part undergo lysosomal degradation to 
prevent overactivation of these activated signaling pathways. LNK may aid in the 
attenuation of the tyrosine kinase activity through endocytic degradation.
In summary, our data identified for the first time several unique functions of LNK in ovarian 
cancer cells. LNK augmented the p-AKT and p-MAPK pathways, enhanced cell adhesion 
and slowed cell migration, and promoted the in vivo tumor growth in murine xenograft 
model. 14-3-3 was identified as one of the LNK binding partner which can suppress LNK 
activity. Our results suggest that in contrast to the findings in hematologic malignancies, the 
adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers. We 
believe that our observations are novel and open a new area of inquiry for this important 
adaptor protein.
Supplementary Material
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Fig. 1. Elevated expression of LNK in various cancers and serum-starved cells
A. LNK expression in various human cancers compared to matched normal tissue. Left 
panel, LNK mRNA levels higher in the normal tissue v/s the cancer samples. Right panel, 
LNK mRNA levels higher in the cancer samples v/s normal tissues. Data are from GEO 
database. B. LNK expression in five different molecular subtypes 31 of ovarian cancer 
patients samples (left panel) and ovarian cancer cell lines (right panel). C. Kaplan-Meier 
plots of overall survival of 316 ovarian cancer patients: comparison of cases with high levels 
(EXP:>2, defined as: > mean + 2SD, left panel) versus low levels (EXP <-2, defined as: < 
mean - 2SD, right panel) of LNK mRNA. P values are calculated by log rank test and 
indicated on the graph. Data are obtained from TCGA (The Cancer Genome Atlas) ovarian 
cancer project using the cBio Cancer Genomics Portal. D. IHC staining of ovarian cancer 
tissue array stained with LNK antibody (Photo of the whole section core of each sample are 
provide in Supplemental Fig 4 and which appear in the same order): #1, Normal ovary 1; #2, 
Normal ovary 2; #3, Benign ovarian tumor; #4, Clear cell ovarian carcinoma; #5, Serous 
Cystadenocarcinoma of the ovary (Grade I); #6, Serous cystadenocarcinoma (Grade II); #7, 
Serous cystadenocarcinoma (Grade III); #8, Serous cystadenocarcinoma (Grade III); #9, 
Endometrioid carcinoma of the ovary (Grade I), #10, Endometrioid carcinoma (Grade II) 
#11, Endometrioid carcinoma (Grade III), #12, Endometrioid carcinoma (Grade III). E. IHC 
staining score of 84 ovarian samples (see Supplementary Material for scoring intensity). F. 
Western blots of endogenous LNK levels in ovarian cancer cell lines (A2008 and C13) and 
melanoma cell lines (M285 and M368) during serum starvation (18 hours, SS) and followed 
by addition of serum (2 hours). Confluent cultures were changed to serum-free medium for 
18 hours, and then switched back to complete medium containing 10% FBS for 2 hours. 
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Western blot was performed to examine the LNK protein at indicated time points. Ctrl 
(control cell grown in the complete medium containing 10% FBS). G Western blot of LNK 
in the ovarian cancer cell line OVCA433 with forced expressed LNK. Cells were serum-
starved (18 hours) followed by serum stimulation (as described above) for 1–3 hours, and 
LNK protein was examined by western blot. β-actin was used as loading control.
Ding et al. Page 16
Oncogene. Author manuscript; available in PMC 2015 September 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 2. Forced expression of LNK renders the cells resistant to death
A. OVCA433 cells with either forced express of LNK or GFP control, were cultured under 
conditions of either serum starvation or nutrient deprivation (50/50 % RPMI/PBS or 10/90 
% RPMI/PBS), or treated with LY294002, Sunitinib, 17-DMAG, Actinomycin D or 
Paclitaxel. Cell survival was determined by MTT colorimetric assay. B. Cells 
overexpressing either LNK or GFP were cultured with RPMI medium with either 0% or 2% 
FBS for 9 days and the viability of the cells was examined by MTT assay. C. Cell resistance 
to death induced by nutrient deprivation (10/90% RPMI/PBS) of OVCAR5, C13 and 
CAOV2, ovarian cancer cells ± forced expression of LNK and MTT colorimetric assay was 
performed. D. Activation status of the AKT/MAPK signaling pathways in OVCA433 cells 
either with (left lane) or without (right lane) forced expression of LNK. Cells were serum-
starved for 9 days and various total and phosphorylated (p-) proteins were examined by 
western blot. E. OVCA433 cells (forced expression of either LNK or GFP control) were 
infected with lentivirus containing shRNA targeting to AKT1 and then cultured under 
conditions of serum starvation. Cell survival was determined by MTT assay (left panel). 
Western blot was performed to examine the silencing of AKT (right panel). Significance 
was calculated by paired student t-test and was defined as: ns (not significant), p > 0.05; * 
p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0.0001.
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Fig. 3. In vitro and In vivo effects of forced expression or silencing of LNK on cell growth
A.B. In vitro effects of either forced expression (A) or silencing (B) of LNK on ovarian 
cancer cell growth. MTT assays were performed in 96 wells plates, and the number of cells 
seeded in each well at point zero is shown. (Mean ± SD, n=6). C. Effect of either forced 
expression or silencing of LNK on the growth of CAOV2, A2008 and OVCAR5 xenografts 
in Nod-SCID mice. 2 million (CAOV2 and A2008) or 6 million (OVCAR5) cells were 
resuspened in FBS, mix with matrigel and subcutaneously injected into both flanks of 
immune deficient Nod-SCID mice. Tumors size and weight were measured after the mice 
were sacrificed on either day 18 (CAOV2, A2008), day 21 (OVCAR5 cell force LNK) or 
day 28 (OVCAR5 silencing LNK). Tumor weights are shown as mean ± sem. D. Western 
blot of the protein extract from the xenograft tumor. E. IHC staining of the xenograft tumor 
(CAOV2 and OVCAR5) with either LNK antibody or H&E.
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Fig. 4. LNK upregulates mitogenic signaling pathways in ovarian cancer cells
A. Phosphorylation status of a number of signaling pathways in OVCA433 and OVCAR5 
cells with forced expression of LNK. Cells were grown in optimal conditions, lysed, total 
protein separated by SDS-PAGE and western bloted with indicated antibodies. B. Western 
blot analysis of phosphorylation status of signaling pathways in A2008, CAOV2 and 
OVCAR5 cells stably silenced for expression of LNK with shRNA. Ctrl (non-target 
shRNA), sh15 and sh16 (shRNA 5715 and 5716, both target LNK). Figs. C.D.E.F.G: 
Phosphorylation status of AKT and MAPK pathways in OVCA433 (C), C13 (D), A2008 
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(E), CAOV2 (F) and OVCAR5 (G) ovarian cancer cells with either forced expression or 
silencing of LNK after serum-starvation overnight, followed by serum- stimulation for 
indicated durations, and Western blot was performed with indicated antibodies. Ctrl cells in 
normal growth conditions, SS (serum-starved overnight), 20–120 min (serum-starved 
overnight followed by serum stimulation for 20–120 minutes). Figs. H, I, J: Correlation of 
expression levels of LNK mRNA and activated (phosphorylated) AKT (panel H), MTOR 
and MAP2K1 (MEK1) (panel I), MAPK (panels J, includes p-ERK1/2, p-JNK1/2 and p-
p38) in 316 ovarian cancer samples [protein data from TCGA ovarian cancer, reverse phase 
protein array (RPPA) dataset].
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Fig. 5. LNK regulates cell adhesion, migration and cell size
A. Overexpression of LNK renders cells more adhesive to tissue culture plate. Cell 
detachment was measured by replacing regular RPMI media with different ratios of PBS to 
RPMI, resulting in media with either 95 %, 99 % or 100 % PBS. Upper panel, photographs 
of cells taken 3 hours after media replacement; lower panel, graphic representation of data. 
B. Upper panel: representative images from wound healing experiments using confluent 
OVCA433 cells overexpressing either GFP or LNK. Pictures were collected at 0, 12 and 16 
hours. Lower panel: graphic display of the size of the gap at 12 and 16 hours after 
‘wounding’, expressed as a percentage of the gap of control at time zero. Results represent 
mean ± SD of 4 experiments. C. Transwell experiments of OVCA433 cells stably 
expressing either LNK or GFP. Cells migrating through the membrane were determined by 
MTT dye staining. Data are expressed as a percentage of migrating cells, expressed as a 
percent of control cells (48 hours), * p≤0.05; ** p≤0.01; *** p≤0.001. D. Overexpression of 
LNK reduces the cell diameter in a panel of ovarian cancer cell lines. Ovarian cancer cell 
lines with either forced expression of LNK or GFP controls were grown in similar, non-
confluent conditions, trypsinized, centrifuged, resuspended in complete media and their cell 
diameters were measured using the Vi-CELL Cell Viability Analyzer (Beckman). E. 
Silencing of the LNK enlarges the diameter of ovarian cancer cell lines. Ovarian cancer cell 
lines which were stably expressing shRNA targeted either to LNK (5715, 5716 and 6095) or 
non-target shRNA as control (Ctrl), were collected and their cell diameters were measured. 
For each cell line, 500~2,000 cells were measured to generate the mean value of the cell 
diameter. Significance was calculated by paired student t-test; and the P values are indicated 
after each bar.
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Fig. 6. Altered gene expression in LNK overexpressing OVCA433 cells
A. Microarray analysis was performed in triplicate using OVCA433 cells either 
overexpressing LNK or GFP (control). Pathway enrichment analysis of genes differentially 
expressed between LNK and control cells was analyzed using the KEGG database. * 
p≤0.05; *** p≤0.001. B. Heat map of altered genes in p53, JAK-STAT and cell adhesion 
pathways. C. Real time PCR validation of prominently altered genes related to cell adhesion 
and ECM (upper panel), p53 signaling, cell cycle and cell death (lower left panel) and 
MAPK pathway (lower right panel) in LNK versus control cells. RQ (Relative 
Quantification of the gene expression after normalization to beta-actin). Results represent 
mean ± SD of quantitative measurments.
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Fig. 7. LC-MS identification of binding partners and phosphorylation sites of LNK
A. Potential LNK binding partners identified by mass spectrometry. Ranking based on the 
mass spectrometry Log (e) value. LNK protein expressed in OVCA433 was 
immunoprecipitated using V5 antibodies; potential binding proteins were detected by LC-
MS as described in Materials and Methods. B. Western blot confirms the serine/threonine 
phosphorylation (p-S/T) of LNK and LNK binding to 14-3-3. LNK protein was pulled down 
from OVCA433 cells overexpressing V5 tagged LNK using V5 antibodies and examined by 
western blot with antibodies against total phosphorylated S/T (upper panel). The membrane 
was stripped and re-probed with antibodies to LNK (middle panel) and 14-3-3 (lower panel). 
IgG L indicated the IgG light chain non-specific band. C. Total proteins from OVCA433 
cells overexpressing LNK were separated into cytoplasmic and nuclear fractions, and 
western blot was performed. Successful separation of cytoplasmic and nuclear proteins was 
confirmed by probing blots with antibody against α-tubulin (cytoplasmic protein) and 
hnRNP (nuclear protein). D. Phosphorylation of LNK identified by LC-MS. 79.9663 
indicates the possible phosphorylation site (molecular weight of phosphoryl group). The 
motifs recognized by the possible binding kinases were predicted using Scansite (http://
scansite.mit.edu/). E. Comparison of the LNK amino acid sequences surrounding the 
phosphorylation sites (S-150 and S-330) in humans and other mammals (phosphorylation 
sites are highlighted with red). F. Silencing of 14-3-3 further reduces the cell diameter of 
OVCAR5 with stable forced expression of LNK. Result are expressed as a percentage of the 
cell infected with non-target shRNA (but force expression of LNK). G. Silencing of 14-3-3 
modestly enhanced in vivo tumor growth of OVCAR5 stably expressing LNK. A total 6 
million cells were resuspened in FBS, mix with matrigel and subcutaneously injected into 
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both flanks of immune deficient Nod-SCID mice. The mice were sacrificed on day 15, 
tumor are pictorially shown and their weights shown as mean ± sem of 10 tumors.
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